Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
(4) - EconoTimes)
EMERYVILLE, Calif., May 01, 2018 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.
The awards were made on May 1, 2018, under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 31,500 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $40.15, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About Zogenix
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
Media: Rachel Lipsitz
Public Relations, INC Research/inVentivHealth
858-449-9575 | [email protected]
